Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress
07:30am, Friday, 10'th Oct 2025
17 abstracts from across the Company's portfolio and pipeline highlight new clinical and real-world data on major depressive disorder and treatment-resistant depression New post-hoc analysis of CAPLYT
Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
02:42am, Friday, 10'th Oct 2025
Johnson & Johnson (NYSE:JNJ) will release earnings results for the third quarter, before the opening bell on Tuesday, Oct. 14.
Johnson & Johnson to Participate in the UBS Global Healthcare Conference
04:24pm, Thursday, 09'th Oct 2025
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the UBS Global Healthcare Conference on Tuesday, November 11th, 2025. Management will participate in a Fireside Chat
Wall Street's Insights Into Key Metrics Ahead of Johnson & Johnson (JNJ) Q3 Earnings
10:15am, Thursday, 09'th Oct 2025
Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its k
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Thursday, 09'th Oct 2025
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Goldman Sachs expects another quarter of outperformance from J&J in Q3
03:11pm, Wednesday, 08'th Oct 2025
Johnson & Johnson (NYSE:JNJ)'s strong year-to-date performance is likely to continue when the healthcare giant reports third quarter earnings on October 14, according to analysts at Goldman Sachs. The
Why Johnson & Johnson (JNJ) is Poised to Beat Earnings Estimates Again
01:11pm, Wednesday, 08'th Oct 2025
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:50am, Wednesday, 08'th Oct 2025
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
09:46am, Wednesday, 08'th Oct 2025
Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.
Why AbbVie and Johnson & Johnson Could Outperform Pfizer
07:17am, Wednesday, 08'th Oct 2025
Pfizer Inc. NYSE: PFE made a strong move higher after it became the first drug manufacturer to sign on as part of the TrumpRx platform. PFE stock is up nearly 14% since its closing price of around $23
Johnson & Johnson ordered to pay $966 million in talc cancer case after jury finds company liable
02:42am, Wednesday, 08'th Oct 2025
A Los Angeles jury ordered Johnson & Johnson to pay $966 million to the family of a woman who died from mesothelioma, finding the company liable in the latest trial alleging its talc pr
Worried About a Recession? 2 Stocks to Buy Now to Prepare Your Portfolio
08:58pm, Tuesday, 07'th Oct 2025
It's impossible to predict with certainty whether a recession is coming, but certain developments sure make it more likely. President Donald Trump's tariff policies could lead to increased prices and
LA County Jury Hits Johnson & Johnson with Nearly $1 Billion Verdict
04:19pm, Tuesday, 07'th Oct 2025
LOS ANGELES--(BUSINESS WIRE)--A Los Angeles County jury has returned damages totaling $966 million, including $950 million in punitive damages, to the family of Mae Moore, who died of mesothelioma in
Johnson & Johnson ordered to pay $966 million after jury finds company liable in talc cancer case
10:50am, Tuesday, 07'th Oct 2025
A Los Angeles jury late on Monday ordered Johnson & Johnson to pay $966 million to the family of a woman who died from mesothelioma, finding the company liable in the latest lawsuit alleging its baby
Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated with the highest dose achieving endoscopic improvement at Week 12 in the Phase 2b ANTHEM-UC
